Patents by Inventor Andre Engling
Andre Engling has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20190117770Abstract: Disclosed is a method and composition for treating a disease associated with target cells expressing CD138 in a multiple dose regimen. An immunoconjugate comprising an engineered targeting antibody targeting CD138 expressing cells and an effector molecule is administered in a multiple dose regimen. The multiple dose regimen comprises at least two doses and the aggregate dose administered within an active treatment cycle is an aggregate maximum tolerable dose (AMTD) or a fraction of the AMTD. The AMTD and/or said fraction exceeds the dose resulting in dose limiting toxicity (DLT) and/or exceeds the maximum tolerable dose (MTD) when the immunoconjugate is administered as a single dose, including as part of a multiple single dose regimen within said active treatment cycle.Type: ApplicationFiled: September 24, 2018Publication date: April 25, 2019Applicants: Biotest AG, ImmunoGen, Inc.Inventors: Gregor Schulz, Frank Osterroth, Thomas Haeder, Christoph Bruecher, Gabriele Niemann, Andre Engling, Christoph Uherek, Benjamin Daelken, Andrea Wartenberg-Demand, Chantal Zuber, Marcus Gutscher, Katrin Bernoester, Martin Koenig
-
Patent number: 10117932Abstract: Disclosed is a method and composition for treating a disease associated with target cells expressing CD138 in a multiple dose regimen. An immunoconjugate comprising an engineered targeting antibody targeting CD138 expressing cells and an effector molecule is administered in a multiple dose regimen. The multiple dose regimen comprises at least two doses and the aggregate dose administered within an active treatment cycle is an aggregate maximum tolerable dose (AMTD) or a fraction of the AMTD. The AMTD and/or said fraction exceeds the dose resulting in dose limiting toxicity (DLT) and/or exceeds the maximum tolerable dose (MTD) when the immunoconjugate is administered as a single dose, including as part of a multiple single dose regimen within said active treatment cycle.Type: GrantFiled: December 7, 2012Date of Patent: November 6, 2018Assignees: BIOTEST AG, IMMUNOGEN INC.Inventors: Gregor Schulz, Frank Osterroth, Thomas Haeder, Christoph Bruecher, Gabriele Niemann, Andre Engling, Christoph Uherek, Benjamin Daelken, Andrea Wartenberg-Demand, Chantal Zuber, Marcus Gutscher, Katrin Bernoester, Martin Koenig
-
Patent number: 9995733Abstract: Provided are methods of screening to identify molecules capable of binding to CD4 and capable of activating CD4+CD25+ regulatory T cells. Further provided are antibodies and antibody fragments capable of activating CD4+CD25+ regulatory T cells and methods and uses involving the antibodies and fragments thereof.Type: GrantFiled: May 30, 2012Date of Patent: June 12, 2018Assignee: BIOTEST AGInventors: Frank Osterroth, Christoph Uherek, Christoph Bruecher, Benjamin Daelken, André Engling, Chantal Zuber, Niklas Czeloth, Holger Wallmeier, Kirsten Völp, Gregor Schulz
-
Patent number: 9605066Abstract: Provided is a humanized or chimeric antibody or fragment thereof capable of binding to interleukin-10 (IL-10), wherein said antibody or fragment thereof is capable of being administered to a subject in the absence of an intolerable increase in the level of pro-inflammatory cytokines. Further provided are methods of treatment involving the use of the antibody or fragment thereof.Type: GrantFiled: August 29, 2014Date of Patent: March 28, 2017Assignee: BIOTEST AGInventors: Frank Osterroth, Christoph Uherek, Christoph Bruecher, Peter Röttgen, Benjamin Daelken, André Engling, Chantal Zuber, Niklas Czeloth, Andrea Wartenberg-Demand, Marcus Gutscher, Judith Wessels-Kranz
-
Patent number: 9540436Abstract: Provided is a humanized or chimeric antibody or fragment thereof capable of binding to interleukin-10 (IL-10), wherein said antibody or fragment thereof: (i) binds to the same region of IL-10 as the IL-10 receptor ? (IL-I10Ra) and is not capable of binding IL-10 when the IL-10 is bound to the IL-10 receptor; and (ii) binds to IL-10 in homodimeric form by binding a discontinuous epitope comprising residues of both monomers. Further provided are related products and methods involving the use of the antibody or fragment thereof.Type: GrantFiled: January 7, 2015Date of Patent: January 10, 2017Assignee: BIOTEST AGInventors: Frank Osterroth, Christoph Uherek, Christoph Bruecher, Peter Röttgen, Benjamin Daelken, André Engling, Chantal Zuber, Niklas Czeloth
-
Patent number: 9289509Abstract: Disclosed are methods and treatment regimes that include the administration of immunconjugates targeting CD138 to combat diseases. The immunoconjugate is either used as the sole active ingredient, as part of a treatment regime or as part of an anticancer combination.Type: GrantFiled: May 5, 2010Date of Patent: March 22, 2016Assignees: Biotest AG, Immunogen Inc.Inventors: Frank Osterroth, Christoph Uherek, Christoph Bruecher, Benjamin Daelken, Andre Engling, Thomas Haeder, Andrea Wartenberg-Demand, Gabriele Niemann, Chantal Zuber, Niklas Czeloth, Silke Aigner, Steffen Zeng, Gregor Schulz
-
Publication number: 20150218270Abstract: Provided is a humanized or chimeric antibody or fragment thereof capable of binding to interleukin-10 (IL-10), wherein said antibody or fragment thereof: (i) binds to the same region of IL-10 as the IL-10 receptor ? (IL-I10Ra) and is not capable of binding IL-10 when the IL-10 is bound to the IL-10 receptor; and (ii) binds to IL-10 in homodimeric form by binding a discontinuous epitope comprising residues of both monomers. Further provided are related products and methods involving the use of the antibody or fragment thereof.Type: ApplicationFiled: January 7, 2015Publication date: August 6, 2015Inventors: Frank OSTERROTH, Christoph UHEREK, Christoph BRUECHER, Peter RÖTTGEN, Benjamin DAELKEN, André ENGLING, Chantal ZUBER, Niklas CZELOTH
-
Publication number: 20150064179Abstract: Provided is a humanized or chimeric antibody or fragment thereof capable of binding to interleukin-10 (1L-10), wherein said antibody or fragment thereof is capable of being administered to a subject in the absence of an intolerable increase in the level of pro-inflammatory cytokines. Further provided are methods of treatment involving the use of the antibody or fragment thereof.Type: ApplicationFiled: August 29, 2014Publication date: March 5, 2015Inventors: FRANK OSTERROTH, CHRISTOPH UHEREK, CHRISTOPH BRUECHER, PETER RÖTTGEN, BENJAMIN DAELKEN, ANDRÉ ENGLING, CHANTAL ZUBER, NIKLAS CZELOTH, ANDREA WARTENBERG-DEMAND, MARCUS GUTSCHER, JUDITH WESSELS-KRANZ
-
Patent number: 8956607Abstract: Provided is a humanized or chimeric antibody or fragment thereof capable of binding to interleukin-10 (IL-10), wherein said antibody or fragment thereof: (i) binds to the same region of IL-10 as the IL-10 receptor ?(IL-I10Ra) and is not capable of binding IL-10 when the IL-10 is bound to the IL- 10 receptor; and (ii) binds to IL-10 in homodimeric form by binding a discontinuous epitope comprising residues of both monomers. Further provided are related products and methods involving the use of the antibody or fragment thereof.Type: GrantFiled: November 30, 2010Date of Patent: February 17, 2015Assignee: Biotest AGInventors: Frank Osterroth, Christoph Uherek, Christoph Bruecher, Peter Röttgen, Benjamin Daelken, André Engling, Chantal Zuber, Niklas Czeloth
-
Patent number: 8852871Abstract: Provided is a humanized or chimeric antibody or fragment thereof capable of binding to interleukin-10 (Th-10), wherein said antibody or fragment thereof is capable of being administered to a subject in the absence of an intolerable increase in the level of pro-inflammatory cytokines. Further provided are methods of treatment involving the use of the antibody or fragment thereof.Type: GrantFiled: November 30, 2010Date of Patent: October 7, 2014Assignee: Biotest AGInventors: Frank Osterroth, Christoph Uherek, Christoph Bruecher, Peter Röttgen, Benjamin Daelken, André Engling, Chantal Zuber, Niklas Czeloth, Andrea Wartenberg-Demand, Marcus Gutscher, Judith Wessels-Kranz
-
Publication number: 20140010828Abstract: Disclosed is a method and composition for treating a disease associated with target cells expressing CD138 in a multiple dose regimen. An immunoconjugate comprising an engineered targeting antibody targeting CD138 expressing cells and an effector molecule is administered in a multiple dose regimen. The multiple dose regimen comprises at least two doses and the aggregate dose administered within an active treatment cycle is an aggregate maximum tolerable dose (AMTD) or a fraction of the AMTD. The AMTD and/or said fraction exceeds the dose resulting in dose limiting toxicity (DLT) and/or exceeds the maximum tolerable dose (MTD) when the immunoconjugate is administered as a single dose, including as part of a multiple single dose regimen within said active treatment cycle.Type: ApplicationFiled: December 7, 2012Publication date: January 9, 2014Applicants: IMMUNOGEN, INC., BIOTEST AGInventors: Gregor Schulz, Frank Osterroth, Thomas Haeder, Christoph Bruecher, Gabriele Niemann, Andre Engling, Christoph Uherek, Benjamin Daelken, Andrea Wartenberg-Demand, Chantal Zuber, Marcus Gutscher, Katrin Bernoester, Martin Koenig
-
Publication number: 20130004513Abstract: Provided are methods of screening to identify molecules capable of binding to CD4 and capable of activating CD4+CD25+ regulatory T cells. Further provided are antibodies and antibody fragments capable of activating CD4+CD25+ regulatory T cells and methods and uses involving the antibodies and fragments thereof.Type: ApplicationFiled: May 30, 2012Publication date: January 3, 2013Inventors: Frank Osterroth, Christoph Uherek, Christoph Bruecher, Benjamin Daelken, André Engling, Chantal Zuber, Niklas Czeloth, Holger Wallmeier, Kirsten Völp, Gregor Schulz
-
Publication number: 20120321618Abstract: Provided is a humanized or chimeric antibody or fragment thereof capable of binding to interleukin-10 (Th-10), wherein said antibody or fragment thereof is capable of being administered to a subject in the absence of an intolerable increase in the level of pro-inflammatory cytokines. Further provided are methods of treatment involving the use of the antibody or fragment thereof.Type: ApplicationFiled: November 30, 2010Publication date: December 20, 2012Applicant: BIOTEST AGInventors: Frank Osterroth, Christoph Uherek, Christoph Bruecher, Peter Röttgen, Benjamin Daelken, André Engling, Chantal Zuber, Niklas Czeloth, Andrea Wartenberg-Demand, Marcus Gutscher, Judith Wessels-Kranz
-
Publication number: 20120321617Abstract: Provided is a humanized or chimeric antibody or fragment thereof capable of binding to interleukin-10 (IL-10), wherein said antibody or fragment thereof: (i) binds to the same region of IL-10 as the 1L-10 receptor ? (IL-I10Ra) and is not capable of binding IL-10 when the IL-10 is bound to the IL-10 receptor; and (ii) binds to IL-10 in homodimeric form by binding a discontinuous epitope comprising residues of both monomers. Further provided are related products and methods involving the use of the antibody or fragment thereof.Type: ApplicationFiled: November 30, 2010Publication date: December 20, 2012Applicant: BIOTEST AGInventors: Frank Osterroth, Christoph Uherek, Christoph Bruecher, Peter Röttgen, Benjamin Daelken, André Engling, Chantal Zuber, Niklas Czeloth
-
Publication number: 20110123554Abstract: Disclosed are methods and treatment regimes that include the administration of immunconjugates targeting CD138 to combat diseases. The immunoconjugate is either used as the sole active ingredient, as part of a treatment regime or as part of an anticancer combination.Type: ApplicationFiled: May 5, 2010Publication date: May 26, 2011Inventors: Frank Osterroth, Christoph Uherek, Christoph Bruecher, Benjamin Daelken, Andre Engling, Thomas Haeder, Andrea Wartenberg-Demand, Gabriele Niemann, Chantal Zuber, Niklas Czeloth, Silke Aigner, Steffen Zeng